To survive and grow rapidly, cancer cells fundamentally change how they produce energy. Rather than using the efficient oxygen-dependent process that normal cells prefer, cancer cells shift to a faster but less efficient method called aerobic glycolysis -- breaking down glucose even when oxygen is available. This switch, known as the Warburg effect, was first described over a century ago and remains one of the defining features of cancer metabolism.
In clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, this metabolic reprogramming is particularly pronounced. The hallmark VHL gene mutation in ccRCC directly activates glycolytic pathways, making kidney cancer especially dependent on this energy strategy. This dependency is not just a curiosity -- it shapes how aggressive the tumor is, how it interacts with the immune system, and potentially how it responds to treatment.
Long non-coding RNAs (lncRNAs) are molecules that regulate gene activity without producing proteins. Some lncRNAs specifically regulate genes involved in glycolysis and are known as glycolysis-related lncRNAs (GRLs). This study investigated whether a combination of GRLs could serve as a reliable prognostic tool and, critically, whether they could predict which ccRCC patients would benefit from immunotherapy.
The researchers began with gene expression data from 530 ccRCC patients from The Cancer Genome Atlas (TCGA-KIRC), randomly split into a training set of 374 patients and a validation set of 156 patients. A separate external validation cohort from the ICGC database (89 patients) was also used to ensure results generalized beyond the original dataset.
First, researchers identified all glycolysis-related genes from established databases, then used WGCNA (Weighted Gene Co-expression Network Analysis) to find lncRNAs whose activity patterns strongly correlated with glycolysis gene activity across all patients. This process yielded 357 candidate glycolysis-related lncRNAs (GRLs) -- all of them potentially connected to the metabolic changes in kidney cancer.
To narrow this list, researchers applied LASSO regression (a statistical method that eliminates redundant predictors) followed by multivariate Cox proportional hazards analysis (which identifies which factors independently predict survival while accounting for other variables). This rigorous two-step process identified the minimal set of lncRNAs that provided the most predictive information: 4 lncRNAs -- LUCAT1, LINC01138, LINC01605, and HOTAIR. Each patient received a numerical risk score based on the weighted expression of these four molecules.
The 4-GRL risk score reliably separated ccRCC patients into high-risk and low-risk groups with substantially different survival outcomes. In the training cohort, the model achieved 1-year AUC of 0.777, 3-year AUC of 0.729, and 5-year AUC of 0.745 -- indicating it correctly predicted survival outcomes approximately 73-78% of the time across different time points. These results held up consistently in both the internal validation cohort and the external ICGC dataset.
Importantly, multivariate Cox analysis confirmed the risk score is an independent prognostic factor: even after accounting for patient age, tumor stage (T, N, M), and tumor grade, the GRL risk score remained a statistically significant predictor of survival. High-risk patients had significantly worse outcomes regardless of their clinical stage, suggesting the model captures biological information not reflected in standard staging.
A nomogram (visual prediction chart) was built combining the GRL risk score with age and tumor stage, allowing clinicians to estimate individual patient survival probabilities at 1, 3, and 5 years. The nomogram performed better than any single variable alone, with calibration analysis confirming that predicted probabilities closely matched actual observed outcomes across all time points.
Analysis of the immune environment revealed a counterintuitive but important finding. High-risk patients had higher overall levels of immune cell infiltration in their tumors compared to low-risk patients -- including more CD8+ T cells, macrophages, and natural killer cells. However, alongside these anti-tumor cells, high-risk tumors also showed elevated levels of immunosuppressive cells including Tregs (regulatory T cells) and M0 macrophages, which dampen immune responses.
High-risk tumors also showed elevated expression of immune checkpoint molecules including PD-1, PD-L1, and CTLA4 -- the exact targets of immune checkpoint inhibitor drugs. This is significant because high checkpoint expression is a marker of immune activation and is often associated with better responses to checkpoint inhibitor therapy. Multiple immunotherapy response prediction algorithms (TIDE, IPS, SubMap) consistently predicted that high-risk patients were more likely to benefit from immune checkpoint inhibitors -- the opposite of what some other prognostic models have found.
The risk score was also significantly correlated with established markers of tumor aggressiveness: higher risk scores were associated with higher clinical T stage, M stage, N stage, and overall AJCC stage. This means the metabolic signature captured by the GRL risk score aligns with how far the cancer has spread and grown -- further validating its biological relevance.
To confirm that LINC01138 and LINC01605 play real biological roles (rather than being statistical associations), researchers conducted laboratory experiments using two kidney cancer cell lines: 769-P and 786-O. Using siRNA (small interfering RNA) -- a genetic tool that selectively silences a single gene -- they suppressed the activity of each lncRNA individually and measured the effect on cancer cell growth.
The results were clear: knockdown of either LINC01138 or LINC01605 significantly inhibited cell proliferation in both cell lines. Cancer cells with reduced LINC01138 or LINC01605 activity grew more slowly and were less viable. This experimental validation demonstrates these are not passive bystanders but functional contributors to kidney cancer cell survival.
Further molecular analysis revealed distinct mechanisms for the two lncRNAs. LINC01605 was positively correlated with HIF1A (a master regulator of the cellular response to low oxygen and a key driver of glycolysis in ccRCC), and was linked to glycolytic pathway activation, cell proliferation signaling (E2F pathway), and processes that enable tumor spread (epithelial-to-mesenchymal transition). LINC01138, by contrast, was negatively correlated with HIF1A and was associated with interferon signaling and immune regulation pathways, suggesting it influences the immune environment rather than metabolism directly. Both lncRNAs showed strong ceRNA (competing endogenous RNA) network activity -- they interact with microRNAs to regulate downstream target genes.
This study establishes a 4-lncRNA glycolysis-related risk signature that can predict both overall survival and immunotherapy response in clear cell renal cell carcinoma. The signature bridges two important aspects of cancer biology -- metabolic reprogramming and immune regulation -- that are increasingly recognized as interconnected in shaping tumor behavior.
The key clinical insight is that this model may help identify which kidney cancer patients are most likely to benefit from immune checkpoint inhibitor therapy. Immunotherapy has transformed kidney cancer treatment, but only a fraction of patients respond. A test based on these 4 lncRNAs could help guide treatment selection, sparing non-responders from treatment side effects while ensuring responders receive these drugs earlier.
The study's primary limitations include its retrospective design using public databases and the relatively small size of the external validation cohort. The experimental validation focused on two cell lines, and future research should confirm these findings in animal models and eventually in prospective clinical trials. Despite these limitations, the integration of metabolic biology, immune analysis, and experimental validation makes this one of the more comprehensive lncRNA-based prognostic studies published for kidney cancer. Translation into a clinical molecular test would require standardized RNA measurement protocols and prospective validation in diverse patient populations.